Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zimmer Biomet Holdings (NYSE: ZBH), PTC Therapeutics (NASDAQ: PTCT) and Jounce Therapeutics (NASDAQ: JNCE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zimmer Biomet Holdings (ZBHResearch Report), PTC Therapeutics (PTCTResearch Report) and Jounce Therapeutics (JNCEResearch Report).

Zimmer Biomet Holdings (ZBH)

Raymond James analyst Lawrence Keusch maintained a Buy rating on Zimmer Biomet Holdings yesterday and set a price target of $200.00. The company’s shares closed last Tuesday at $172.93, close to its 52-week high of $180.36.

According to TipRanks.com, Keusch is a 4-star analyst with an average return of 6.4% and a 66.7% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Baxter International, Intuitive Surgical, and Becton Dickinson.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zimmer Biomet Holdings with a $187.47 average price target, representing a 7.8% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $195.00 price target.

See today’s analyst top recommended stocks >>

PTC Therapeutics (PTCT)

Raymond James analyst Danielle Brill reiterated a Buy rating on PTC Therapeutics yesterday and set a price target of $70.00. The company’s shares closed last Tuesday at $38.47, close to its 52-week low of $38.01.

According to TipRanks.com, Brill is a 4-star analyst with an average return of 12.9% and a 49.3% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $65.17 average price target, which is a 59.4% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.

Jounce Therapeutics (JNCE)

Raymond James analyst Steven Seedhouse maintained a Hold rating on Jounce Therapeutics yesterday. The company’s shares closed last Tuesday at $8.53.

According to TipRanks.com, Seedhouse is a 3-star analyst with an average return of 6.5% and a 42.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Alexion Pharmaceuticals, and Apellis Pharmaceuticals.

Jounce Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.